John Daley, MD
Family Medicine · Derry, NHNPI 1720058944
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 235 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,708, 2.1 times the $817 reported in 2019. Among family medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$987
- Pfizer$550
- Lilly USA, LLC$277
- GSK$240
- Boehringer Ingelheim$235
- AstraZeneca$230
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,573100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $987 |
| Pfizer | 41 | $550 |
| Lilly USA, LLC | 16 | $277 |
| GSK | 14 | $240 |
| Boehringer Ingelheim | 13 | $235 |
| AstraZeneca | 12 | $230 |
| Inspire Medical Systems, Inc. | 6 | $226 |
| Amgen | 9 | $165 |
| Abbott | 2 | $157 |
| Novartis | 6 | $149 |
| Merck | 7 | $111 |
| Astellas Pharma US Inc | 6 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $97 |
| Johnson & Johnson | 5 | $96 |
| Biogen | 4 | $88 |
| Novo Nordisk | 5 | $83 |
| Bayer | 4 | $70 |
| Lundbeck LLC | 3 | $63 |
| Viiv Healthcare Company | 3 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $55 |
| Ardelyx, Inc. | 2 | $51 |
| Phathom Pharmaceuticals, Inc. | 2 | $50 |
| Otsuka America Pharmaceutical, Inc. | 3 | $46 |
| Exact Sciences | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Antares Pharma, Inc. | 1 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Sanofi | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Cequr Corporation | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,573 in reported general payments places this provider in the 95th percentile of 397 family medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 114 | $120,946 |
| OzempicSemaglutide | 50 | $83,322 |
| JardianceEmpagliflozin | 36 | $55,005 |
| XareltoRivaroxaban | 36 | $37,711 |
| TrulicityDulaglutide | 21 | $30,260 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $20,505 |
| Spiriva RespimatTiotropium Bromide | 20 | $19,529 |
| MounjaroTirzepatide | 14 | $14,386 |
| OxycontinOxycodone Hcl | 11 | $14,155 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $7,741 |
| Atorvastatin Calcium | 757 | $7,340 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $7,044 |
| Oxcarbazepine | 14 | $6,066 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 128 | $5,811 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $550 | $120,946114 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $235 | $95,04074 claims |
| Novo NordiskOzempic | $83 | $83,32250 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $277 | $44,64635 claims |
| Johnson & JohnsonXarelto | $96 | $37,71136 claims |
| AstraZenecaSymbicort | $230 | $4,73912 claims |
| GSKBreo Ellipta | $240 | $4,59812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 397 family medicine providers in New Hampshire.
Other family medicine in Derry
- Robyn StewartDerry$8K
- Douglas DrefferDerry$5K
- John WheelerDerry$5K
- Michael MaroldaDerry$5K
- Katelyn IsherwoodDerry$3K
- Sarah MuraiDerry$2K
- Cristi EgenolfDerry$2K
- Kristin BroughtonDerry$1K
- Scott LowDerry$1K
- Mark BallentynePortsmouth$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.